Financial Performance - Revenue decreased by approximately 7.2% from HKD 245.5 million in FY2024 to HKD 227.9 million in FY2025[2] - Gross profit fell by about 13.5% from HKD 182.1 million in FY2024 to HKD 157.5 million in FY2025, with a gross margin decline of 5.1 percentage points to 69.1%[2] - The company recorded a net loss of approximately HKD 23.0 million in FY2025, compared to a net profit of HKD 13.0 million in FY2024[2] - Total revenue from customer contracts was HKD 227,868,000 in 2025, down from HKD 245,490,000 in 2024, representing a decrease of about 7.1%[14] - The group reported a pre-tax loss of HKD 27,587,000 in 2025 compared to a profit of HKD 18,677,000 in 2024[24] - Basic earnings per share for 2025 were calculated based on a loss attributable to equity shareholders of HKD 23,009,000, compared to a profit of HKD 12,965,000 in 2024[25] - The group recorded a net loss of approximately HKD 23.0 million in fiscal year 2025, compared to a net profit of approximately HKD 13.0 million in fiscal year 2024, attributed to increased promotional offers and higher advertising and employee costs[72] Dividend Information - The board does not recommend the payment of a final dividend for FY2025, while a final dividend of HKD 20,000,040 was declared for FY2024[2] - No final dividend was proposed for 2025, while a final dividend of HKD 0.15 per share was declared for 2024, totaling HKD 20,000,000[28] - Cash dividends declared by a subsidiary amounted to HKD 30,000,000 for the year ended December 31, 2024[29] - The company approved a dividend of 15 HKD cents per share for the fiscal year 2025, totaling 20,000 thousand HKD, compared to no dividend in 2024[30] - The board of directors does not recommend the distribution of a final dividend for the reporting period, compared to a final dividend of HKD 20,000,040 in 2024[89] Asset and Liability Changes - Total assets decreased from HKD 197.5 million in FY2024 to HKD 159.9 million in FY2025, reflecting a decline in current assets[4] - Non-current assets decreased from HKD 44.5 million in FY2024 to HKD 34.3 million in FY2025, primarily due to a reduction in property and equipment[4] - The company's net asset value decreased from HKD 187.2 million in FY2024 to HKD 144.2 million in FY2025[5] - Cash and cash equivalents decreased significantly from HKD 119.2 million in FY2024 to HKD 78.2 million in FY2025[4] - Trade receivables decreased from 26,367 thousand HKD in 2024 to 24,187 thousand HKD in 2025, reflecting a decline of approximately 8.0%[31] - Trade payables increased from 3,782 thousand HKD in 2024 to 3,934 thousand HKD in 2025, representing a growth of approximately 4.0%[32] - Other payables and accrued expenses rose significantly from 15,350 thousand HKD in 2024 to 21,150 thousand HKD in 2025, marking an increase of about 37.5%[32] Revenue Breakdown - Customer contract revenue for retail business decreased to HKD 136,707,000 in 2025 from HKD 145,641,000 in 2024, a decline of approximately 6.4%[14] - Customer contract revenue for wholesale business decreased to HKD 87,619,000 in 2025 from HKD 94,157,000 in 2024, a decline of approximately 6.9%[14] - Revenue from retail business decreased by approximately HKD 8.9 million or 6.1%, from about HKD 145.6 million in FY2024 to approximately HKD 136.7 million in FY2025[62] - Revenue from wholesale business decreased by approximately HKD 6.6 million or 7.0%, from about HKD 94.2 million in FY2024 to approximately HKD 87.6 million in FY2025[63] - Revenue from consignment arrangements decreased by approximately HKD 2.2 million or 38.6%, from about HKD 5.7 million in FY2024 to approximately HKD 3.5 million in FY2025[64] Cost and Expense Changes - Employee costs rose to HKD 88,066,000 in 2025 from HKD 76,033,000 in 2024, an increase of about 15.8%[19] - Depreciation expenses increased to HKD 22,683,000 in 2025 from HKD 20,998,000 in 2024, an increase of approximately 8.0%[21] - Sales and distribution costs increased by approximately HKD 30.0 million or 28.4% in FY2025, primarily due to increased marketing and promotional expenses[67] - Administrative and other operating expenses increased by approximately HKD 12.1 million or 31.0% in FY2025, mainly due to higher employee costs and increased depreciation from more retail stores[68] - Financing costs decreased by approximately HKD 62,000 or 5.5% to about HKD 1,074,000 in the fiscal year 2025, primarily due to the absence of bank loan interest[70] Share Issuance and Capital Changes - The company issued 33,333,600 new ordinary shares at a cash price of 3.75 HKD per share, raising approximately 125,001 thousand HKD[34] - The share capital increased to 2,000,000,000 shares with a nominal value of 0.01 HKD per share as of December 31, 2024[33] - The company’s cash expenses related to share issuance were approximately 11,417 thousand HKD, which reduced the share premium generated from the issuance[34] Strategic Initiatives and Future Plans - The company plans to allocate approximately HKD 94.4 million from the net proceeds, with 35.7% (HKD 33.7 million) dedicated to marketing and promotional activities to enhance brand awareness by December 2027[85] - The company aims to expand and optimize its sales network, allocating 37.8% (HKD 35.7 million) of the proceeds for this purpose, with HKD 33.3 million expected to be utilized by December 2027[85] - The company is focusing on developing innovative packaging and expanding into new product categories, including Western health products and various external Chinese medicines[93] - The company plans to open new retail stores in selected locations to enhance customer accessibility and capture a larger market share[94] - The company will improve its online sales platform to better serve customers who prefer online shopping, capitalizing on the growing e-commerce demand in the health product sector[94] Governance and Compliance - The Audit Committee, composed of three independent non-executive directors, has reviewed and approved the consolidated financial statements for the reporting period[103] - The company's auditor, BDO Limited, confirmed that the financial data in the preliminary announcement is consistent with the amounts in the draft consolidated financial statements[104] - The company has adopted the standards set out in Appendix C3 of the Listing Rules as a code of conduct for directors' securities transactions[101] - Independent non-executive directors had opportunities to discuss governance and board matters during the reporting period[99] - The Board of Directors consists of both executive and independent non-executive directors, ensuring a balanced governance structure[107]
草姬集团(02593) - 2025 - 年度业绩